Promoter shareholding decreased slightly YoY (-0.03%), while sector Promoters remained stable, indicating a lack of confidence from insiders.

Institutional holdings in Parmax Pharma remained unchanged, contrasting with sector trends where some stocks saw significant institutional buying, suggesting a broader sector weakness.

Public shareholding increased by 1.14% YoY, but this reactive trend does not offset the lack of engagement from smart money, confirming overall selling pressure.